Top entities: Alnylam Pharmaceuticals, Kessler Topaz Meltzer & Check.

What category does this event fall under?

Regulatory — classified as securities investigation.

What is the sentiment of coverage?

Aggregate sentiment score: -60 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

What were the key actions taken?

Alnylam Pharmaceuticals lowered guidance · Kessler Topaz Meltzer & Check launched investigation Alnylam Pharmaceuticals · The Law Offices of Frank R. Cruz launched investigation Alnylam Pharmaceuticals

Is this event still developing?

This is an active story, last updated Aug 16, 2026. Coverage continues to evolve.

Regulatory securities investigation

Alnylam guidance cut triggers securities investigation

Q: When did this event occur?

First reported Jul 30, 2026; last updated Aug 16, 2026.

Q: What is the market impact?

General. Alnylam's stock dropped over 28% after the guidance cut, reflecting investor disappointment and eroding market confidence.

Analysis based on 18 articles · First reported Jul 30, 2026 · Last updated Aug 16, 2026

Sentiment

-60

Attention

Articles

Market Impact

General

Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Market Impact

Alnylam's stock dropped over 28% after the guidance cut, reflecting investor disappointment and eroding market confidence. The securities investigation adds legal and reputational risk, potentially prolonging negative sentiment and increasing volatility for the company's shares.

Pharmaceuticals Legal Services

Event Summary

On July 30, 2026, Alnylam Pharmaceuticals reported its second quarter 2026 financial results, announcing a reduction in its full-year 2026 TTR product sales guidance by approximately $200 million. The company attributed the cut to learnings from the initial phase of its launch in the evolving ATTR-CM market, including the normalization of growth in second-line volume after satisfying pent-up demand. Following the announcement, Alnylam's stock price fell over 28%. Subsequently, the law firm Kessler Topaz Meltzer & Check, LLP announced it is investigating potential violations of federal securities laws by Alnylam on behalf of investors who suffered significant losses. The investigation focuses on whether Alnylam made misleading statements or failed to disclose material information regarding its product sales prospects.

Key Actions

100 Alnylam Pharmaceuticals lowered guidance

80 Kessler Topaz Meltzer & Check launched investigation Alnylam Pharmaceuticals

70 The Law Offices of Frank R. Cruz launched investigation Alnylam Pharmaceuticals

Entities Involved

stock

Alnylam Pharmaceuticals

Alnylam is the subject of the investigation and the company that cut its revenue guidance, causing a 28% stock drop. The guidance reduction and subsequent investigation negatively impact its financial outlook and investor confidence.

Importance 100.0 Sentiment -70.0

priv

Kessler Topaz Meltzer & Check

Kessler Topaz Meltzer & Check is the law firm conducting the investigation, which could lead to securities litigation. The firm benefits from potential legal fees and recoveries, while the investigation adds pressure on Alnylam.

Importance 60.0 Sentiment 20.0

ERGEN INTELLIGENCE

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard